These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 23573743)
21. Licence to save: a UK survey of anti-VEGF use for the eye in 2015. Shalaby AK; Lewis K; Bush K; Meredith PR; Di Simplicio S; Lockwood AJ Eye (Lond); 2016 Nov; 30(11):1404-1406. PubMed ID: 27518544 [No Abstract] [Full Text] [Related]
22. Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration? Micieli JA Can J Ophthalmol; 2011 Dec; 46(6):549-51. PubMed ID: 22153646 [No Abstract] [Full Text] [Related]
23. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? Lotery A; MacEwen C BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142 [No Abstract] [Full Text] [Related]
24. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318 [TBL] [Abstract][Full Text] [Related]
25. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration]. Li H; Li X; Xie F Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975 [TBL] [Abstract][Full Text] [Related]
26. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds. Torjesen I BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948 [No Abstract] [Full Text] [Related]
27. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Jeganathan VS; Verma N Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163 [TBL] [Abstract][Full Text] [Related]
28. Minister rules out use of Avastin over Lucentis for wet AMD. Kmietowicz Z BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175 [No Abstract] [Full Text] [Related]
29. Off-label prescribing in macular degeneration. McCartney M BMJ; 2011 Oct; 343():d6778. PubMed ID: 22012651 [No Abstract] [Full Text] [Related]
30. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Almony A; Mansouri A; Shah GK; Blinder KJ Can J Ophthalmol; 2011 Apr; 46(2):182-5. PubMed ID: 21708088 [TBL] [Abstract][Full Text] [Related]
31. Intravitreous bevacizumab adult safety data: the evidence so far. Al-Qureshi S; Shaikh S Clin Exp Ophthalmol; 2012; 40(1):3-5. PubMed ID: 22304024 [No Abstract] [Full Text] [Related]
33. [Vision for patients with macular degeneration]. Paukstadt W MMW Fortschr Med; 2007 Jan; 149(3):10-2. PubMed ID: 17619375 [No Abstract] [Full Text] [Related]
34. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458 [TBL] [Abstract][Full Text] [Related]
35. Comparing ranibizumab with bevacizumab. Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243 [No Abstract] [Full Text] [Related]
36. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us? Aujla JS Clin Exp Optom; 2012 Sep; 95(5):538-40. PubMed ID: 22621684 [TBL] [Abstract][Full Text] [Related]
37. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)]. Holz FG MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376 [No Abstract] [Full Text] [Related]